Emerging applications for ferumoxytol as a contrast agent in MRI

Journal of Magnetic Resonance Imaging

Volumn 41, Issue 4, 2015, Pages 884-898

  Bashir, Mustafa R ^a   Bhatti, Lubna ^a   Marin, Daniele ^a   Nelson, Rendon C ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

feraheme; ferumoxytol; SPIO; USPIO

Indexed keywords

FERUMOXYTOL; GADOFOSVESET; GADOLINIUM; CONTRAST MEDIUM; MAGNETITE;

ABDOMINAL PARENCHYMAL IMAGING; AORTIC IMAGING; ARTERY TRANSPLANTATION; BRAIN DAMAGE; BRAIN TUMOR; CELL LABELING; DILUTION; DRUG DISTRIBUTION; DRUG SAFETY; ENDOLEAK; HUMAN; IMAGING; LOWER EXTREMITY DEEP VEIN THROMBOSIS; LYMPH NODE IMAGING; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RELAXATION TIME; RENAL ARTERY; REVIEW; SCINTIGRAPHY; STEM CELL; TRANSPLANT RENAL ARTERY IMAGING; VASCULAR LESION; VENOUS IMAGING; FORECASTING; IMAGE ENHANCEMENT; MAGNETIC RESONANCE ANGIOGRAPHY; PROCEDURES; REPRODUCIBILITY; SENSITIVITY AND SPECIFICITY; TRENDS;

CONTRAST MEDIA; FERROSOFERRIC OXIDE; FORECASTING; HUMANS; IMAGE ENHANCEMENT; MAGNETIC RESONANCE ANGIOGRAPHY; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY;

EID: 84925293041     PISSN: 10531807     EISSN: 15222586     Source Type: Journal    
DOI: 10.1002/jmri.24691     Document Type: Review

References (104)

1. Rajagopalan S, Prince M,. Magnetic resonance angiographic techniques for the diagnosis of arterial disease. Cardiol Clin 2002; 20: 501-512, v.
2. Rengier F, Geisbusch P, Vosshenrich R, et al. State-of-the-art aortic imaging. Part I. Fundamentals and perspectives of CT and MRI. Vasa 2013; 42: 395-412.
3. Schubert R,. Coarctation of the abdominal aorta: demonstration of a rare anomaly using contrast-enhanced MR-angiography. Vasa 2009; 38: 66-71.
4. Dosa E, Guillaume DJ, Haluska M, et al. Magnetic resonance imaging of intracranial tumors: intra-patient comparison of gadoteridol and ferumoxytol. Neuro Oncol 2011; 13: 251-260.
5. Gahramanov S, Muldoon LL, Varallyay CG, et al. Pseudoprogression of glioblastoma after chemo- and radiation therapy: diagnosis by using dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging with ferumoxytol versus gadoteridol and correlation with survival. Radiology 2013; 266: 842-852.
6. Bashir MR, Gupta RT, Davenport MS, et al. Hepatocellular carcinoma in a North American population: does hepatobiliary MR imaging with Gd-EOB-DTPA improve sensitivity and confidence for diagnosis? J Magn Reson Imaging 2013; 37: 398-406.
7. Gandhi SN, Brown MA, Wong JG, Aguirre DA, Sirlin CB,. MR contrast agents for liver imaging: what, when, how. Radiographics 2006; 26: 1621-1636.
8. Bremerich J, Bilecen D, Reimer P,. MR angiography with blood pool contrast agents. Eur Radiol 2007; 17: 3017-3024.
9. Goyen M,. Gadofosveset-enhanced magnetic resonance angiography. Vasc Health Risk Manag 2008; 4: 1-9.
10. Hadizadeh DR, Kukuk GM, Fahlenkamp UL, et al. Simultaneous MR arteriography and venography with blood pool contrast agent detects deep venous thrombosis in suspected arterial disease. AJR Am J Roentgenol 2012; 198: 1188-1195.
11. Cohan RH, Davenport MS, Dillman JR, et al. ACR Manual on Contrast Media v8. 2012; Available from: http://www.acr.org/ ~/media/ACR/Documents/PDF/QualitySafety/Resources/Contrast%20Manual/FullManual.pdf.
12. Broome DR, Girguis MS, Baron PW, Cottrell AC, Kjellin I, Kirk GA,. Gadodiamide-associated nephrogenic systemic fibrosis: why radiologists should be concerned. AJR Am J Roentgenol 2007; 188: 586-592.
13. Grobner T,. Gadolinium-a specific trigger for the development of nephrogenic fibrosing dermopathy and nephrogenic systemic fibrosis? Nephrol Dial Transplant 2006; 21: 1104-1108.
14. Marckmann P, Skov L, Rossen K, et al. Nephrogenic systemic fibrosis: suspected causative role of gadodiamide used for contrast-enhanced magnetic resonance imaging. J Am Soc Nephrol 2006; 17: 2359-2362.
15. Sadowski EA, Bennett LK, Chan MR, et al. Nephrogenic systemic fibrosis: risk factors and incidence estimation. Radiology 2007; 243: 148-157.
16. Shabana WM, Cohan RH, Ellis JH, et al. Nephrogenic systemic fibrosis: a report of 29 cases. AJR Am J Roentgenol 2008; 190: 736-741.
17. Wood JC, Enriquez C, Ghugre N, et al. MRI R2 and R2∗ mapping accurately estimates hepatic iron concentration in transfusion-dependent thalassemia and sickle cell disease patients. Blood 2005; 106: 1460-1465.
18. Rohrer M, Bauer H, Mintorovitch J, Requardt M, Weinmann HJ,. Comparison of magnetic properties of MRI contrast media solutions at different magnetic field strengths. Invest Radiol 2005; 40: 715-724.
19. Corot C, Robert P, Idee JM, Port M,. Recent advances in iron oxide nanocrystal technology for medical imaging. Adv Drug Deliv Rev 2006; 58: 1471-1504.
20. Bashir MR, Mody R, Neville A, et al. Retrospective assessment of the utility of an iron-based agent for contrast-enhanced magnetic resonance venography in patients with endstage renal diseases. J Magn Reson Imaging 2014; 40: 113-118.
21. McCullough BJ, Kolokythas O, Maki JH, Green DE,. Ferumoxytol in clinical practice: Implications for MRI. J Magn Reson Imaging 2013; 37: 1476-1479.
22. Storey P, Lim RP, Chandarana H, et al. MRI assessment of hepatic iron clearance rates after USPIO administration in healthy adults. Invest Radiol 2012; 47: 717-724.
23. Schieda N,. Parenteral ferumoxytol interaction with magnetic resonance imaging: a case report, review of the literature and advisory warning. Insights Imaging 2013; 4: 509-512.
24. McCullough BJ, Kolokythas O, Maki JH, Green DE,. Ferumoxytol in clinical practice: implications for MRI. J Magn Reson Imaging 2013; 37: 1476-1479.
25. Pai AB, Garba AO,. Ferumoxytol: a silver lining in the treatment of anemia of chronic kidney disease or another dark cloud? J Blood Med 2012; 3: 77-85.
26. Bailie GR,. Comparison of rates of reported adverse events associated with i.v. iron products in the United States. Am J Health Syst Pharm 2012; 69: 310-320.
27. Santhos S, Podaralla P, Miller B,. Anaphylaxis with elevated tryptase after administration of intravenous ferumoxytol. NDT Plus 2010; 1322: 13-14.
28. Food-and-Drug-Administration. Feraheme Package Insert. 2013 [cited 2013 December 6]; Available from: http://www.accessdata.fda.gov/drugsatfda-docs/label/2009/022180lbl.pdf
29. Food-and-Drug-Administration. Isovue Package Insert. 2013 [cited 2013 December 6]; Available from: http://www.accessdata.fda.gov/drugsatfda-docs/label/2012/018735s054lbl.pdf
30. Kubik-Huch RA, Gottstein-Aalame NM, Frenzel T, et al. Gadopentetate dimeglumine excretion into human breast milk during lactation. Radiology 2000; 216: 555-558.
31. Rofsky NM, Weinreb JC, Litt AW,. Quantitative analysis of gadopentetate dimeglumine excreted in breast milk. J Magn Reson Imaging 1993; 3: 131-132.
32. Wang PI, Chong ST, Kielar AZ, et al. Imaging of pregnant and lactating patients: part 1, evidence-based review and recommendations. AJR Am J Roentgenol 2012; 198: 778-784.
33. Neimatallah MA, Chenevert TL, Carlos RC, et al. Subclavian MR arteriography: reduction of susceptibility artifact with short echo time and dilute gadopentetate dimeglumine. Radiology 2000; 217: 581-586.
34. Fananapazir G, Marin D, Suhocki PV, Kim CY, Bashir MR,. Vascular artifact mimicking thrombosis on MR imaging using ferumoxytol as a contrast agent in abdominal vascular assessment. J Vasc Interv Radiol 2014; 25: 969-976.
35. Li W, Tutton S, Vu AT, et al. First-pass contrast-enhanced magnetic resonance angiography in humans using ferumoxytol, a novel ultrasmall superparamagnetic iron oxide (USPIO)-based blood pool agent. J Magn Reson Imaging 2005; 21: 46-52.
36. Ersoy H, Jacobs P, Kent CK, Prince MR,. Blood pool MR angiography of aortic stent-graft endoleak. AJR Am J Roentgenol 2004; 182: 1181-1186.
37. Prince MR, Zhang HL, Chabra SG, Jacobs P, Wang Y,. A pilot investigation of new superparamagnetic iron oxide (ferumoxytol) as a contrast agent for cardiovascular MRI. J Xray Sci Technol 2003; 11: 231-240.
38. Stabi KL, Bendz LM,. Ferumoxytol use as an intravenous contrast agent for magnetic resonance angiography. Ann Pharmacother 2011; 45: 1571-1575.
39. Leung DA, Hagspiel KD, Angle JF, Spinosa DJ, Matsumoto AH, Butty S,. MR angiography of the renal arteries. Radiol Clin North Am 2002; 40: 847-865.
40. Bruno S, Remuzzi G, Ruggenenti P,. Transplant renal artery stenosis. J Am Soc Nephrol 2004; 15: 134-141.
41. Bashir MR, Jaffe TA, Brennan TV, Patel UD, Ellis MJ,. Renal transplant imaging using magnetic resonance angiography with a nonnephrotoxic contrast agent. Transplantation 2013; 96: 91-96.
42. Sigovan M, Gasper W, Alley HF, Owens CD, Saloner D,. USPIO-enhanced MR angiography of arteriovenous fistulas in patients with renal failure. Radiology 2012; 265: 584-590.
43. Cohen AT, Agnelli G, Anderson FA, et al. Venous thromboembolism (VTE) in Europe. The number of VTE events and associated morbidity and mortality. Thromb Haemost 2007; 98: 756-764.
44. Enden T, Storas TH, Negard A, et al. Visualization of deep veins and detection of deep vein thrombosis (DVT) with balanced turbo field echo (b-TFE) and contrast-enhanced T1 fast field echo (CE-FFE) using a blood pool agent (BPA). J Magn Reson Imaging 2010; 31: 416-424.
45. Hansch A, Betge S, Poehlmann G, et al. Combined magnetic resonance imaging of deep venous thrombosis and pulmonary arteries after a single injection of a blood pool contrast agent. Eur Radiol 2011; 21: 318-325.
46. Li W, Salanitri J, Tutton S, et al. Lower extremity deep venous thrombosis: evaluation with ferumoxytol-enhanced MR imaging and dual-contrast mechanism-preliminary experience. Radiology 2007; 242: 873-881.
47. Lim ST, Sohn MH, Kwak JY, Yim CY,. Multiple hepatic adenomas: Tc-99m RBC liver SPECT findings with pathologic correlation. Clin Nucl Med 2002; 27: 270-274.
48. Schillaci O, Danieli R, Manni C, Capoccetti F, Simonetti G,. Technetium-99m-labelled red blood cell imaging in the diagnosis of hepatic haemangiomas: the role of SPECT/CT with a hybrid camera. Eur J Nucl Med Mol Imaging 2004; 31: 1011-1015.
49. Martinez-Lazaro R, Dominguez P, Pascau J, Bittini A, Lafuente J, Desco M,. Usefulness of Tc-99m RBC SPECT/MRI fusion imaging in small suspected hepatic hemangiomas. Clin Nucl Med 2004; 29: 844-845.
50. Milot L, Haider M, Foster L, McGregor C, Law C,. Gadofosveset trisodium in the investigation of focal liver lesions in noncirrhotic liver: Early experience. J Magn Reson Imaging 2012; 36: 738-742.
51. Hanna RF, Kased N, Kwan SW, et al. Double-contrast MRI for accurate staging of hepatocellular carcinoma in patients with cirrhosis. AJR Am J Roentgenol 2008; 190: 47-57.
52. Muhi A, Ichikawa T, Motosugi U, et al. Diagnosis of colorectal hepatic metastases: Contrast-enhanced ultrasonography versus contrast-enhanced computed tomography versus superparamagnetic iron oxide-enhanced magnetic resonance imaging with diffusion-weighted imaging. J Magn Reson Imaging 2010; 32: 1132-1140.
53. Okada T, Sasaki F, Kamiyama T, et al. Focal nodular hyperplasia of the liver: usefulness of superparamagnetic iron oxide-enhanced magnetic resonance imaging. J Pediatr Surg 2005; 40: E21-25.
54. Gunn AJ, Seethamraju RT, Hedgire S, Elmi A, Daniels GH, Harisinghani MG,. Imaging behavior of the normal adrenal on ferumoxytol-enhanced MRI: preliminary findings. AJR Am J Roentgenol 2013; 201: 117-121.
55. Sielska M, Przanowski P, Wylot B, et al. Distinct roles of CSF family cytokines in macrophage infiltration and activation in glioma progression and injury response. J Pathol 2013; 230: 310-321.
56. Hamilton BE, Nesbit GM, Dosa E, et al. Comparative analysis of ferumoxytol and gadoteridol enhancement using T1- and T2-weighted MRI in neuroimaging. AJR Am J Roentgenol 2011; 197: 981-988.
57. Farrell BT, Hamilton BE, Dosa E, et al. Using iron oxide nanoparticles to diagnose CNS inflammatory diseases and PCNSL. Neurology 2013; 81: 256-263.
58. Chalouhi N, Dumont AS, Randazzo C, et al. Management of incidentally discovered intracranial vascular abnormalities. Neurosurg Focus 2011; 31: E1.
59. Jayaraman T, Berenstein V, Li X, et al. Tumor necrosis factor alpha is a key modulator of inflammation in cerebral aneurysms. Neurosurgery 2005; 57: 558-564; discussion 64.
60. Jayaraman T, Paget A, Shin YS, et al. TNF-alpha-mediated inflammation in cerebral aneurysms: a potential link to growth and rupture. Vasc Health Risk Manag 2008; 4: 805-817.
61. Chalouhi N, Ali MS, Jabbour PM, et al. Biology of intracranial aneurysms: role of inflammation. J Cereb Blood Flow Metab 2012; 32: 1659-1676.
62. Hasan D, Chalouhi N, Jabbour P, et al. Early change in ferumoxytol-enhanced magnetic resonance imaging signal suggests unstable human cerebral aneurysm: a pilot study. Stroke 2012; 43: 3258-3265.
63. Hasan DM, Chalouhi N, Jabbour P, Magnotta VA, Kung DK, Young WL,. Imaging aspirin effect on macrophages in the wall of human cerebral aneurysms using ferumoxytol-enhanced MRI: preliminary results. J Neuroradiol 2013; 40: 187-191.
64. Hasan DM, Chalouhi N, Jabbour P, et al. Evidence that acetylsalicylic acid attenuates inflammation in the walls of human cerebral aneurysms: preliminary results. J Am Heart Assoc 2013; 2: e000019.
65. Chen Y, Zhu W, Bollen AW, et al. Evidence of inflammatory cell involvement in brain arteriovenous malformations. Neurosurgery 2008; 62: 1340-1349; discussion 1349-1350.
66. Chen Y, Pawlikowska L, Yao JS, et al. Interleukin-6 involvement in brain arteriovenous malformations. Ann Neurol 2006; 59: 72-80.
67. Gaigalaite V, Ozheraitene V, Kalibatene D, Laurikenas K, Sabaliauskene Z,. [Association between structure of atherosclerotic plaques in carotid arteries and myocardial infarction.] Kardiologiia 2013; 53: 21-25.
68. Pinelli A, Trivulzio S, Rossoni G, Redaelli R, Brenna S,. Factors involved in sudden coagulation observed in patients with acute myocardial infarction. In Vivo 2012; 26: 1021-1025.
69. Marnane M, Prendeville S, McDonnell C, et al. Plaque inflammation and unstable morphology are associated with early stroke recurrence in symptomatic carotid stenosis. Stroke 2014; 45: 801-806.
70. Tahara N, Tahara A, Honda A, et al. Molecular imaging of vascular inflammation. Curr Pharm Des 2013; 20: 2439-2437.
71. Libby P, Aikawa M,. Stabilization of atherosclerotic plaques: new mechanisms and clinical targets. Nat Med 2002; 8: 1257-1262.
72. Libby P,. Current concepts of the pathogenesis of the acute coronary syndromes. Circulation 2001; 104: 365-372.
73. Naghavi M, Libby P, Falk E, et al. From vulnerable plaque to vulnerable patient: a call for new definitions and risk assessment strategies: Part I. Circulation 2003; 108: 1664-1672.
74. Stary HC, Chandler AB, Dinsmore RE, et al. A definition of advanced types of atherosclerotic lesions and a histological classification of atherosclerosis. A report from the Committee on Vascular Lesions of the Council on Arteriosclerosis, American Heart Association. Circulation 1995; 92: 1355-1374.
75. Schmitz SA, Coupland SE, Gust R, et al. Superparamagnetic iron oxide-enhanced MRI of atherosclerotic plaques in Watanabe hereditable hyperlipidemic rabbits. Invest Radiol 2000; 35: 460-471.
76. Schmitz SA, Taupitz M, Wagner S, Wolf KJ, Beyersdorff D, Hamm B,. Magnetic resonance imaging of atherosclerotic plaques using superparamagnetic iron oxide particles. J Magn Reson Imaging 2001; 14: 355-361.
77. Schmitz SA, Taupitz M, Wagner S, et al. Iron-oxide-enhanced magnetic resonance imaging of atherosclerotic plaques: postmortem analysis of accuracy, inter-observer agreement, and pitfalls. Invest Radiol 2002; 37: 405-411.
78. Kooi ME, Cappendijk VC, Cleutjens KB, et al. Accumulation of ultrasmall superparamagnetic particles of iron oxide in human atherosclerotic plaques can be detected by in vivo magnetic resonance imaging. Circulation 2003; 107: 2453-2458.
79. Herborn CU, Vogt FM, Lauenstein TC, et al. Magnetic resonance imaging of experimental atherosclerotic plaque: comparison of two ultrasmall superparamagnetic particles of iron oxide. J Magn Reson Imaging 2006; 24: 388-393.
80. Li X, Kramer MC, van der Loos CM, et al. A pattern of disperse plaque microcalcifications identifies a subset of plaques with high inflammatory burden in patients with acute myocardial infarction. Atherosclerosis 2011; 218: 83-89.
81. Bobryshev YV, Killingsworth MC, Lord RS, Grabs AJ,. Matrix vesicles in the fibrous cap of atherosclerotic plaque: possible contribution to plaque rupture. J Cell Mol Med 2008; 12: 2073-2082.
82. Li W, Ostblom M, Xu LH, et al. Cytocidal effects of atheromatous plaque components: the death zone revisited. FASEB J 2006; 20: 2281-2290.
83. Wagner S, Schnorr J, Ludwig A, et al. Contrast-enhanced MR imaging of atherosclerosis using citrate-coated superparamagnetic iron oxide nanoparticles: calcifying microvesicles as imaging target for plaque characterization. Int J Nanomed 2013; 8: 767-779.
84. Mumprecht V, Detmar M,. Lymphangiogenesis and cancer metastasis. J Cell Mol Med 2009; 13: 1405-1416.
85. Foster PJ, Dunn EA, Karl KE, et al. Cellular magnetic resonance imaging: in vivo imaging of melanoma cells in lymph nodes of mice. Neoplasia 2008; 10: 207-216.
86. Cserni G,. Metastases in axillary sentinel lymph nodes in breast cancer as detected by intensive histopathological work up. J Clin Pathol 1999; 52: 922-924.
87. Anzai Y, Piccoli CW, Outwater EK, et al. Evaluation of neck and body metastases to nodes with ferumoxtran 10-enhanced MR imaging: phase III safety and efficacy study. Radiology 2003; 228: 777-788.
88. Koh DM, Brown G, Temple L, et al. Rectal cancer: mesorectal lymph nodes at MR imaging with USPIO versus histopathologic findings-initial observations. Radiology 2004; 231: 91-99.
89. Harisinghani MG, Saini S, Weissleder R, et al. MR lymphangiography using ultrasmall superparamagnetic iron oxide in patients with primary abdominal and pelvic malignancies: radiographic-pathologic correlation. AJR Am J Roentgenol 1999; 172: 1347-1351.
90. Heesakkers RA, Jager GJ, Hovels AM, et al. Prostate cancer: detection of lymph node metastases outside the routine surgical area with ferumoxtran-10-enhanced MR imaging. Radiology 2009; 251: 408-414.
91. Guimaraes R, Clement O, Bittoun J, Carnot F, Frija G,. MR lymphography with superparamagnetic iron nanoparticles in rats: pathologic basis for contrast enhancement. AJR Am J Roentgenol 1994; 162: 201-207.
92. Tatsumi Y, Tanigawa N, Nishimura H, et al. Preoperative diagnosis of lymph node metastases in gastric cancer by magnetic resonance imaging with ferumoxtran-10. Gastric Cancer 2006; 9: 120-128.
93. Rockall AG, Sohaib SA, Harisinghani MG, et al. Diagnostic performance of nanoparticle-enhanced magnetic resonance imaging in the diagnosis of lymph node metastases in patients with endometrial and cervical cancer. J Clin Oncol 2005; 23: 2813-2821.
94. Motomura K, Izumi T, Tateishi S, et al. Correlation between the area of high-signal intensity on SPIO-enhanced MR imaging and the pathologic size of sentinel node metastases in breast cancer patients with positive sentinel nodes. BMC Med Imaging 2013; 13: 32.
95. McDermott S, Thayer SP, Fernandez-Del Castillo C, Mino-Kenudson M, Weissleder R, Harisinghani MG,. Accurate prediction of nodal status in preoperative patients with pancreatic ductal adenocarcinoma using next-gen nanoparticle. Transl Oncol 2013; 6: 670-675.
96. Neuwelt EA, Varallyay CG, Manninger S, et al. The potential of ferumoxytol nanoparticle magnetic resonance imaging, perfusion, and angiography in central nervous system malignancy: a pilot study. Neurosurgery 2007; 60: 601-611; discussion 611-612.
97. Varallyay CG, Muldoon LL, Gahramanov S, et al. Dynamic MRI using iron oxide nanoparticles to assess early vascular effects of antiangiogenic versus corticosteroid treatment in a glioma model. J Cereb Blood Flow Metab 2009; 29: 853-860.
98. Thompson EM, Guillaume DJ, Dosa E, et al. Dual contrast perfusion MRI in a single imaging session for assessment of pediatric brain tumors. J Neurooncol 2012; 109: 105-114.
99. Gruessner AC, Sutherland DE, Gruessner RW,. Long-term outcome after pancreas transplantation. Curr Opin Organ Transplant 2012; 17: 100-105.
100. Toso C, Isse K, Demetris AJ, et al. Histologic graft assessment after clinical islet transplantation. Transplantation 2009; 88: 1286-1293.
101. Jirak D, Kriz J, Herynek V, et al. MRI of transplanted pancreatic islets. Magn Reson Med 2004; 52: 1228-1233.
102. Borot S, Crowe LA, Parnaud G, et al. Quantification of islet loss and graft functionality during immune rejection by 3-Tesla MRI in a rat model. Transplantation 2013; 96: 438-444.
103. Khurana A, Nejadnik H, Chapelin F, et al. Ferumoxytol: a new, clinically applicable label for stem-cell tracking in arthritic joints with MRI. Nanomedicine (Lond) 2013; 8: 1969-1983.
104. Khurana A, Chapelin F, Beck G, et al. Iron administration before stem cell harvest enables MR imaging tracking after transplantation. Radiology 2013; 269: 186-197.